---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-134386"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:09:00.238253+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma reports $93.8M cash; enters non-binding term sheet for up to $100M royalty financing

## Summary
- Preliminary cash, cash equivalents and short-term investments of $93.8M as of March 31, 2023.
- Non-binding term sheet for structured royalty financing up to $100M with an insider investor (>5% holder).
- Initial $30M at closing, additional tranches based on milestones; deal expected Q2 2023 if definitive.
- Collaboration agreement with affiliate development company; joint steering committee planned.
- Mavodelpar (REN001) royalty payments would apply if approved in US or EU.

## SEC filing metadata
- accession: 0001193125-23-134386
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/0001193125-23-134386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312523134386/d133319d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-134386
- JSON: https://secwatch.observer/filing/0001193125-23-134386.json
- Plain text: https://secwatch.observer/filing/0001193125-23-134386.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.